Levi & Korsinsky is investigating the Board of Directors of Tiens Biotech Group (USA), Inc. (“Tiens Biotech” or “the Company”) (AMEX: TBV) for possible breaches of fiduciary duty and other violations of state law in connection with the receipt of a merger proposal from the Company’s Chairman and CEO, Jinyuan Li. Under the terms of the transaction, Tiens Biotech shareholders would receive $1.72 per share of Tiens Biotech stock they own. Mr. Li currently owns more than 95% of the Company’s outstanding shares.
Click here to learn how to join the action: http://www.zlk.com/tiens-biotech, or call: 877-363-5972.
The investigation concerns whether the Tiens Biotech Board of Directors is adequately shopping the Company and taking the necessary steps to obtain the best possible price for Tiens Biotech shareholders. In particular, Tiens Biotech reported a book value of $2.67 per share for the most recent quarter.
If you own common stock in Tiens Biotech and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com.Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.